The Prognostic Impact of NF-kappaB P105, Vimentin, E-cadherin and Par6 Expression in Epithelial and Stromal Compartment in Non-small-cell Lung Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Oct 16

PMID 18854838

Citations 72

Authors

S Al-Saad

K Al-Shibli

T Donnem

M Persson

R M Bremnes

L-T Busund

Affiliations

Soon will be listed here.

Abstract

Vimentin, nuclear factor-kappaB (NF-kappaB) p105, fascin, E-cadherin, TGF-beta, Par6 and atypical PKC are molecular markers that play an important role in cell differentiation. Herein, we investigate their prognostic impact in primary non-small-cell carcinoma (NSCLC). Tumour tissue samples from 335 resected patients with stage I-IIIA were used. Tissue microarrays were constructed from duplicate cores of both neoplastic cells and stromal cells and were immunohistochemically evaluated. In univariate analyses, high tumour epithelial cell expressions of NF-kappaB p105 (P=0.02) and E-cadherin (P=0.03) were positive prognostic indicators for disease-specific survival (DSS), whereas high tumour epithelial cell expression of vimentin (P=0.001) was a negative prognostic indicator. High expression of NF-kappaB p105 (P=0.001) and Par6 (P=0.0001) in the stromal compartment correlated with a good prognosis. In multivariate analyses, the tumour epithelial cell expression of NF-kappaB p105 (P=0.0001) and vimentin (P=0.005) and the stromal cell expression of NF-kappaB p105 (P=0.007) and Par6 (P=0.0001) were independent prognostic factors for DSS. High expression of NF-kappaB p105 and low expression of vimentin in tumour epithelial cells are independent predictors of better survival in primary NSCLC. In stromal cells, high expressions of NF-kappaB p105 and Par6 are both favourable independent prognostic indicators.

Citing Articles

Comparative Proteomics of ccRCC Cell Lines to Identify Kidney Cancer Progression Factors.

Park J, Sim H, Lee E, Kim B, Chung J, Ha Y Cancer Genomics Proteomics. 2024; 21(6):645-652.

PMID: 39467626 PMC: 11534031. DOI: 10.21873/cgp.20480.

Lowering expression of Epsin-3 inhibits migration and invasion of lung adenocarcinoma cells by inhibiting the epithelial-mesenchymal transition.

Li Y, Zhang P, Tang G, Zhong J, Wang Z, Zhu B Sci Rep. 2024; 14(1):17069.

PMID: 39048677 PMC: 11269644. DOI: 10.1038/s41598-024-68193-1.

Unclear tumor border in magnetic resonance imaging as a prognostic factor of squamous cell cervical cancer.

Sato M, Tamauchi S, Yoshida K, Yoshihara M, Ikeda Y, Yoshikawa N Sci Rep. 2023; 13(1):15392.

PMID: 37717112 PMC: 10505168. DOI: 10.1038/s41598-023-42787-7.

LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer.

Tong D, Wang X, Liu L, Wen T, Chen Q, Huang C Cancer Gene Ther. 2023; 30(11):1498-1512.

PMID: 37542131 PMC: 10645587. DOI: 10.1038/s41417-023-00654-7.

Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.

Berr A, Wiese K, Dos Santos G, Koch C, Anekalla K, Kidd M Oncogene. 2023; 42(25):2074-2087.

PMID: 37161053 PMC: 10275760. DOI: 10.1038/s41388-023-02703-9.

References

Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M . Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer. 2000; 83(4):480-6. PMC: 2374649. DOI: 10.1054/bjoc.2000.1345. View

Thiery J, Huang R . Linking epithelial-mesenchymal transition to the well-known polarity protein Par6. Dev Cell. 2005; 8(4):456-8. DOI: 10.1016/j.devcel.2005.03.002. View

Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker G, Dietze O . Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol. 2001; 193(2):181-9. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V. View

Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K . Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001; 91(5):964-71. View

Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S . E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg. 2001; 71(3):949-54; discussion 954-5. DOI: 10.1016/s0003-4975(00)02545-5. View

Pelletier M, Edwardes M, Michel R, Halwani F, MORIN J . Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg. 2001; 44(3):180-8. PMC: 3699112. View

Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J . Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol. 2002; 156(2):299-313. PMC: 2199233. DOI: 10.1083/jcb.200109037. View

Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52(1):23-47. DOI: 10.3322/canjclin.52.1.23. View

Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams J . Fascins, and their roles in cell structure and function. Bioessays. 2002; 24(4):350-61. DOI: 10.1002/bies.10070. View

10.

Karin M, Cao Y, Greten F, Li Z . NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2(4):301-10. DOI: 10.1038/nrc780. View

11.

Bremnes R, Veve R, Gabrielson E, Hirsch F, Baron A, Bemis L . High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002; 20(10):2417-28. DOI: 10.1200/JCO.2002.08.159. View

12.

Fidler I . Critical determinants of metastasis. Semin Cancer Biol. 2002; 12(2):89-96. DOI: 10.1006/scbi.2001.0416. View

13.

Regala R, Weems C, Jamieson L, Khoor A, Edell E, Lohse C . Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res. 2005; 65(19):8905-11. DOI: 10.1158/0008-5472.CAN-05-2372. View

14.

Toloza E, DAmico T . Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005; 17(3):199-204. DOI: 10.1053/j.semtcvs.2005.08.001. View

15.

Bremnes R, Camps C, Sirera R . Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2005; 51(2):143-58. DOI: 10.1016/j.lungcan.2005.09.005. View

16.

Costea D, Kulasekara K, Neppelberg E, Johannessen A, Vintermyr O . Species-specific fibroblasts required for triggering invasiveness of partially transformed oral keratinocytes. Am J Pathol. 2006; 168(6):1889-97. PMC: 1606610. DOI: 10.2353/ajpath.2006.050843. View

17.

Zhang Z, Ma J, Li N, Sun N, Wang C . Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg. 2006; 82(1):243-8. DOI: 10.1016/j.athoracsur.2006.01.049. View

18.

Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A . Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006; 25(36):4975-85. DOI: 10.1038/sj.onc.1209511. View

19.

von Rahden B, Stein H, Feith M, Puhringer F, Theisen J, Siewert J . Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog. 2006; 45(10):786-94. DOI: 10.1002/mc.20259. View

20.

Chaffer C, Brennan J, Slavin J, Blick T, Thompson E, Williams E . Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66(23):11271-8. DOI: 10.1158/0008-5472.CAN-06-2044. View